Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Aug 7, 2026

Palvella Therapeutics, Inc. (PVLA)

A forensic read on Palvella Therapeutics, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

D · Weak — demands caution

Forensic grade

Grey Zone

Financial health

6.1

Distress distance

Clean

Earnings quality

Forensic signals

-149.1%

ROE

$2.3B

Market cap

303.4%

Revenue growth

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Palvella Therapeutics, Inc. earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads 6.1, placing it in the Grey zone. 3 forensic signals were flagged in its latest SEC filings, led by stock-based comp load.

What the filings flag

247% of rev

FY2025

Stock-based comp load. Stock-based compensation ran 247% of revenue in FY2025 — about $0.57 per diluted share. The cost of it is not in the cash flow — no cash left the business — it is in the count: holders gave up about 21.3% of the company a year, and that rate is not falling. That is the figure to weigh, not the share of free cash flow.

-$49.5M

FY2023–FY2025

Cash burn vs. reported loss. Over FY2023–FY2025, the company reported a cumulative net loss of $40.5M against operating cash flow of -$49.5M. Cash burn ran heavier than the reported loss — something outside net income (working capital, a cash item not in the P&L) is consuming cash faster than the loss alone implies.

n/m (stock split)

FY2021–FY2025

Share count (stock split). Diluted share count changed -83% over the last 4 years to FY2025, but that includes a large one-time change around FY2023 consistent with a stock split or reverse split, not gradual buybacks or issuance — a split changes the count with NO effect on any holder's proportional ownership, so the raw -35.4%/yr figure isn't a real buyback/dilution read here.

Key fundamentals

Latest Revenue$2.6M

Revenue Growth YoY+303.4%

Revenue CAGR (3yr)-53.6%

Net Margin-1610.6%

Return on Equity-149.1%

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Palvella Therapeutics, Inc.'s actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Aug 7, 2026. Forensic signals flag probability, not certainty.